<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">20595652</PMID>
      <DateCompleted>
        <Year>2010</Year>
        <Month>09</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1524-4571</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>107</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2010</Year>
              <Month>Aug</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Circulation research</Title>
          <ISOAbbreviation>Circ Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy.</ArticleTitle>
        <Pagination>
          <StartPage>512</StartPage>
          <EndPage>519</EndPage>
          <MedlinePgn>512-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCRESAHA.110.221481</ELocationID>
        <Abstract>
          <AbstractText Label="RATIONALE" NlmCategory="BACKGROUND">The Purkinje fiber network has been proposed as the source of arrhythmogenic Ca(2+) release events in catecholaminergic polymorphic ventricular tachycardia (CPVT), yet evidence supporting this mechanism at the cellular level is lacking.</AbstractText>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We sought to determine the frequency and severity of spontaneous Ca(2+) release events and the response to the antiarrhythmic agent flecainide in Purkinje cells and ventricular myocytes from RyR2(R4496C/+) CPVT mutant mice and littermate controls.</AbstractText>
          <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">We crossed RyR2(R4496C/+) knock-in mice with the newly described Cntn2-EGFP BAC transgenic mice, which express a fluorescent reporter gene in cells of the cardiac conduction system, including the distal Purkinje fiber network. Isolated ventricular myocytes (EGFP(-)) and Purkinje cells (EGFP(+)) from wild-type hearts and mutant hearts were distinguished by epifluorescence and intracellular Ca(2+) dynamics recorded by microfluorimetry. Both wild-type and RyR2(R4496C/+) mutant Purkinje cells displayed significantly slower kinetics of activation and relaxation compared to ventricular myocytes of the same genotype, and tau(decay) in the mutant Purkinje cells was significantly slower than that observed in wild-type Purkinje cells. Of the 4 groups studied, RyR2(R4496C/+) mutant Purkinje cells were also most likely to develop spontaneous Ca(2+) release events, and the number of events per cell was also significantly greater. Furthermore, with isoproterenol treatment, although all 4 groups showed increases in the frequency of arrhythmogenic Ca(2+(i)) events, the RyR2(R4496C/+) Purkinje cells responded with the most profound abnormalities in intracellular Ca(2+) handling, including a significant increase in the frequency of unstimulated Ca(2+(i)) events and the development of alternans, as well as isolated and sustained runs of triggered beats. Both Purkinje cells and ventricular myocytes from wild-type mice showed suppression of spontaneous Ca(2+) release events with flecainide, whereas in RyR2(R4496C/+) mice, the Purkinje cells were preferentially responsive to drug. In contrast, the RyR2 blocker tetracaine was equally efficacious in mutant Purkinje cells and ventricular myocytes.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Purkinje cells display a greater propensity to develop abnormalities in intracellular Ca(2+) handling than ventricular myocytes. This proarrhythmic behavior is enhanced by disease-causing mutations in the RyR2 Ca(2+) release channel and greatly exacerbated by catecholaminergic stimulation, with the development of arrhythmogenic triggered beats. These data support the concept that Purkinje cells are critical contributors to arrhythmic triggers in animal models and humans with CPVT and suggest a broader role for the Purkinje fiber network in the genesis of ventricular arrhythmias.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kang</LastName>
            <ForeName>Guoxin</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>The Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, NY 10016, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Giovannone</LastName>
            <ForeName>Steven F</ForeName>
            <Initials>SF</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Nian</ForeName>
            <Initials>N</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Fang-Yu</ForeName>
            <Initials>FY</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Priori</LastName>
            <ForeName>Silvia G</ForeName>
            <Initials>SG</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fishman</LastName>
            <ForeName>Glenn I</ForeName>
            <Initials>GI</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01HL64757</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL081336</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL081336-05</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01HL081336</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL064757</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL082727-04</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01HL82727</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL082727</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL064757-09</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>GGP06007</GrantID>
            <Acronym>TI_</Acronym>
            <Agency>Telethon</Agency>
            <Country>Italy</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2010</Year>
          <Month>07</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Circ Res</MedlineTA>
        <NlmUniqueID>0047103</NlmUniqueID>
        <ISSNLinking>0009-7330</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SY7Q814VUP</RegistryNumber>
          <NameOfSubstance UI="D002118">Calcium</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000889" MajorTopicYN="N">Anti-Arrhythmia Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008817" MajorTopicYN="N">Mice, Mutant Strains</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011689" MajorTopicYN="N">Purkinje Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019837" MajorTopicYN="N">Ryanodine Receptor Calcium Release Channel</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2010</Year>
          <Month>7</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2010</Year>
          <Month>7</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2010</Year>
          <Month>9</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">20595652</ArticleId>
        <ArticleId IdType="mid">NIHMS221764</ArticleId>
        <ArticleId IdType="pmc">PMC2930621</ArticleId>
        <ArticleId IdType="doi">10.1161/CIRCRESAHA.110.221481</ArticleId>
        <ArticleId IdType="pii">CIRCRESAHA.110.221481</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Cerrone M, Napolitano C, Priori SG. Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation. Heart Rhythm. 2009;6:1652–1659.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19879546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11208676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69:1378–1384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1235548</ArticleId>
            <ArticleId IdType="pubmed">11704930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myers DC, Fishman GI. Toward an understanding of the genetics of murine cardiac pacemaking and conduction system development. Anat Rec A Discov Mol Cell Evol Biol. 2004;280:1018–1021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15368345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pennisi DJ, Rentschler S, Gourdie RG, Fishman GI, Mikawa T. Induction and patterning of the cardiac conduction system. Int J Dev Biol. 2002;46:765–775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12382942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer DH, Lazzara R, Hoffman BF. Interrelationship between automaticity and conduction in Purkinje fibers. Circ Res. 1967;21:537–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6057710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerrone M, Noujaim SF, Tolkacheva EG, Talkachou A, O'Connell R, Berenfeld O, Anumonwo J, Pandit SV, Vikstrom K, Napolitano C, Priori SG, Jalife J. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2007;101:1039–1048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2515360</ArticleId>
            <ArticleId IdType="pubmed">17872467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Di Maio A, Ter Keurs HE, Franzini-Armstrong C. T-tubule profiles in Purkinje fibres of mammalian myocardium. J Muscle Res Cell Motil. 2007;28:115–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17572852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirose M, Stuyvers B, Dun W, Ter Keurs H, Boyden PA. Wide long lasting perinuclear Ca2+ release events generated by an interaction between ryanodine and IP3 receptors in canine Purkinje cells. J Mol Cell Cardiol. 2008;45:176–184.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2566512</ArticleId>
            <ArticleId IdType="pubmed">18586264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vassalle M, Lin CI. Calcium overload and cardiac function. J Biomed Sci. 2004;11:542–565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15316129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maruyama M, Joung B, Tang L, Shinohara T, On YK, Han S, Choi EK, Kim DH, Shen MJ, Weiss JN, Lin SF, Chen PS. Diastolic intracellular calcium-membrane voltage coupling gain and postshock arrhythmias: role of purkinje fibers and triggered activity. Circ Res. 106:399–408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2818796</ArticleId>
            <ArticleId IdType="pubmed">19926871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rawling DA, Joyner RW, Overholt ED. Variations in the functional electrical coupling between the subendocardial Purkinje and ventricular layers of the canine left ventricle. Circ Res. 1985;57:252–261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4017197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huelsing DJ, Spitzer KW, Pollard AE. Electrotonic suppression of early afterdepolarizations in isolated rabbit Purkinje myocytes. Am J Physiol Heart Circ Physiol. 2000;279:H250–259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10899064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben Caref E, Boutjdir M, Himel HD, El-Sherif N. Role of subendocardial Purkinje network in triggering torsade de pointes arrhythmia in experimental long QT syndrome. Europace. 2008;10:1218–1223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18757866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morley GE, Danik SB, Bernstein S, Sun Y, Rosner G, Gutstein DE, Fishman GI. Reduced intercellular coupling leads to paradoxical propagation across the Purkinje-ventricular junction and aberrant myocardial activation. Proc Natl Acad Sci U S A. 2005;102:4126–4129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC554832</ArticleId>
            <ArticleId IdType="pubmed">15753312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han W, Chartier D, Li D, Nattel S. Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation. 2001;104:2095–2100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11673352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han W, Bao W, Wang Z, Nattel S. Comparison of ion-channel subunit expression in canine cardiac Purkinje fibers and ventricular muscle. Circ Res. 2002;91(9):790–797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12411393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyden PA, Pinto JM. Reduced calcium currents in subendocardial Purkinje myocytes that survive in the 24- and 48-hour infarcted heart. Circulation. 1994;89:2747–2759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8205689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeck C, Pinto J, Boyden P. Transient outward currents in subendocardial Purkinje myocytes surviving in the infarcted heart. Circulation. 1995;92:465–473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7634462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinto JM, Boyden PA. Reduced inward rectifying and increased E-4031-sensitive K+ current density in arrhythmogenic subendocardial purkinje myocytes from the infarcted heart. J Cardiovasc Electrophysiol. 1998;9:299–311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9554735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinto JM, Sosunov EA, Gainullin RZ, Rosen MR, Boyden PA. Effects of mibefradil, a T-type calcium current antagonist, on electrophysiology of Purkinje fibers that survived in the infarcted canine heart. J Cardiovasc Electrophysiol. 1999;10:1224–1235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10517656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyden PA, Pu J, Pinto J, Keurs HE. Ca(2+) transients and Ca(2+) waves in purkinje cells : role in action potential initiation. Circ Res. 2000;86:448–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4289140</ArticleId>
            <ArticleId IdType="pubmed">10700450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pallante BA, Giovannone S, Liu FY, Zhang J, Liu N, Kang G, Dun W, Boyden PA, Fishman GI. Contactin-2 Expression in the Cardiac Purkinje Fiber Network. Circ Arrhythm Electrophysiol. 2010;3:186–194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3068837</ArticleId>
            <ArticleId IdType="pubmed">20110552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerrone M, Colombi B, Santoro M, di Barletta MR, Scelsi M, Villani L, Napolitano C, Priori SG. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res. 2005;96:e77–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15890976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, Imbriani M, Napolitano C, Lai FA, Priori SG. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res. 2006;99:292–298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16825580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380–383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2904954</ArticleId>
            <ArticleId IdType="pubmed">19330009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hilliard FA, Steele DS, Laver D, Yang Z, Le Marchand SJ, Chopra N, Piston DW, Huke S, Knollmann BC. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. J Mol Cell Cardiol. 48:293–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2813417</ArticleId>
            <ArticleId IdType="pubmed">19835880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venetucci LA, Trafford AW, Diaz ME, O'Neill SC, Eisner DA. Reducing ryanodine receptor open probability as a means to abolish spontaneous Ca2+ release and increase Ca2+ transient amplitude in adult ventricular myocytes. Circ Res. 2006;98:1299–1305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16614307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez-Velasco M, Rueda A, Rizzi N, Benitah JP, Colombi B, Napolitano C, Priori SG, Richard S, Gomez AM. Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2009;104:201–209. 212p following 209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2796688</ArticleId>
            <ArticleId IdType="pubmed">19096022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang D, Xiao B, Zhang L, Chen SR. Enhanced basal activity of a cardiac Ca2+ release channel (ryanodine receptor) mutant associated with ventricular tachycardia and sudden death. Circ Res. 2002;91:218–225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12169647</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang D, Xiao B, Yang D, Wang R, Choi P, Zhang L, Cheng H, Chen SR. RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR) Proc Natl Acad Sci U S A. 2004;101:13062–13067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC516517</ArticleId>
            <ArticleId IdType="pubmed">15322274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sedej S, Heinzel FR, Walther S, Dybkova N, Wakula P, Groborz J, Gronau P, Maier LS, Vos MA, Lai FA, Napolitano C, Priori SG, Kockskamper J, Pieske B. Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovasc Res. 2010;87:50–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20080988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyden PA, Albala A, Dresdner KP., Jr Electrophysiology and ultrastructure of canine subendocardial Purkinje cells isolated from control and 24-hour infarcted hearts. Circ Res. 1989;65:955–970.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2791230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu N, Ruan Y, Priori SG. Catecholaminergic polymorphic ventricular tachycardia. Prog Cardiovasc Dis. 2008;51:23–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18634915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu N, Priori SG. Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin. Cardiovasc Res. 2008;77:293–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18006488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizzi N, Liu N, Napolitano C, Nori A, Turcato F, Colombi B, Bicciato S, Arcelli D, Spedito A, Scelsi M, Villani L, Esposito G, Boncompagni S, Protasi F, Volpe P, Priori SG. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ Res. 2008;103:298–306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18583715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bogun F, Good E, Reich S, Elmouchi D, Igic P, Tschopp D, Dey S, Wimmer A, Jongnarangsin K, Oral H, Chugh A, Pelosi F, Morady F. Role of Purkinje fibers in post-infarction ventricular tachycardia. J Am Coll Cardiol. 2006;48:2500–2507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17174189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi M, Kobayashi Y, Iwasaki YK, Morita N, Miyauchi Y, Kato T, Takano T. Novel mechanism of postinfarction ventricular tachycardia originating in surviving left posterior Purkinje fibers. Heart Rhythm. 2006;3:908–918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16876739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishima I, Nogami A, Tsuboi H, Sone T. Verapamil-sensitive left anterior fascicular ventricular tachycardia associated with a healed myocardial infarction: changes in the delayed Purkinje potential during sinus rhythm. J Interv Card Electrophysiol. 2008;22:233–237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18600438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha AM, Schmidt M, Marschang H, Gutleben K, Ritscher G, Brachmann J, Marrouche NF. Role of left ventricular scar and Purkinje-like potentials during mapping and ablation of ventricular fibrillation in dilated cardiomyopathy. Pacing Clin Electrophysiol. 2009;32:286–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19272055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haissaguerre M, Extramiana F, Hocini M, Cauchemez B, Jais P, Cabrera JA, Farre J, Leenhardt A, Sanders P, Scavee C, Hsu LF, Weerasooriya R, Shah DC, Frank R, Maury P, Delay M, Garrigue S, Clementy J. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation. 2003;108:925–928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12925452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haissaguerre M, Shah DC, Jais P, Shoda M, Kautzner J, Arentz T, Kalushe D, Kadish A, Griffith M, Gaita F, Yamane T, Garrigue S, Hocini M, Clementy J. Role of Purkinje conducting system in triggering of idiopathic ventricular fibrillation. Lancet. 2002;359:677–678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11879868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi S, Yano M, Suetomi T, Ono M, Tateishi H, Mochizuki M, Xu X, Uchinoumi H, Okuda S, Yamamoto T, Koseki N, Kyushiki H, Ikemoto N, Matsuzaki M. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol. 2009;53:1993–2005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2764410</ArticleId>
            <ArticleId IdType="pubmed">19460614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miquerol L, Meysen S, Mangoni M, Bois P, van Rijen HV, Abran P, Jongsma H, Nargeot J, Gros D. Architectural and functional asymmetry of the His-Purkinje system of the murine heart. Cardiovasc Res. 2004;63:77–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15194464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Severs NJ, Rothery S, Dupont E, Coppen SR, Yeh HI, Ko YS, Matsushita T, Kaba R, Halliday D. Immunocytochemical analysis of connexin expression in the healthy and diseased cardiovascular system. Microsc Res Tech. 2001;52:301–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11180622</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
